J
John W. Shiver
Researcher at Merck & Co.
Publications - 42
Citations - 2446
John W. Shiver is an academic researcher from Merck & Co.. The author has contributed to research in topics: Virus & Vaccination. The author has an hindex of 25, co-authored 42 publications receiving 2380 citations. Previous affiliations of John W. Shiver include Johns Hopkins University & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
Danilo R. Casimiro,Fubao Wang,William A. Schleif,Xiaoping Liang,Zhiqiang Zhang,Timothy W. Tobery,Mary-Ellen Davies,Adrian B. McDermott,David H. O’Connor,Arthur Fridman,Ansu Bagchi,Lynda G. Tussey,Andrew J. Bett,Adam C. Finnefrock,Tong-Ming Fu,Aimin Tang,Keith A. Wilson,Minchun Chen,Helen C. Perry,Gwendolyn J. Heidecker,Daniel C. Freed,Anthony Carella,Kara Punt,Kara J. Sykes,Lingyi Huang,Virginia I. Ausensi,Margaret Bachinsky,Usha Sadasivan-Nair,David I. Watkins,Emilio A. Emini,John W. Shiver +30 more
TL;DR: The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SIVmac239 challenge, and virus control was short-lived.
Journal ArticleDOI
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Frances Priddy,Deborah D. Brown,James G. Kublin,Kathleen Monahan,David Wright,Jacob Lalezari,Steven Santiago,Michael Marmor,Michelle Lally,Richard M. Novak,Stephen J. Brown,Priya Kulkarni,Sheri Dubey,Lisa S. Kierstead,Danilo R. Casimiro,Robin Mogg,Mark J. DiNubile,John W. Shiver,Randi Y. Leavitt,Michael N. Robertson,Devan V. Mehrotra,Erin Quirk +21 more
TL;DR: The vaccine was generally well tolerated and induced cell-mediated immune responses against human immunodeficiency virus type 1 peptides in most healthy adults and vaccination in a proof-of-concept trial with use of this vaccine was discontinued because of lack of efficacy.
Journal ArticleDOI
Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239
Nancy A. Wilson,Jason S. Reed,Gnankang Napoé,Shari M. Piaskowski,Andy Szymanski,Jessica Furlott,Edna J. Gonzalez,Levi Yant,Nicholas J. Maness,Gemma E. May,Taeko Soma,Matthew R. Reynolds,Eva G. Rakasz,Richard Rudersdorf,Adrian B. McDermott,Adrian B. McDermott,David H. O’Connor,Thomas C. Friedrich,David B. Allison,Amit Patki,Louis J. Picker,Dennis R. Burton,Jing Lin,Lingyi Huang,Deepa Patel,Gwendolyn Heindecker,Jiang Fan,Michael P. Citron,Melanie Horton,Fubao Wang,Xiaoping Liang,John W. Shiver,Danilo R. Casimiro,David I. Watkins +33 more
TL;DR: Investigation of whether vaccine-induced cellular immunity in the absence of any Env-specific antibodies can control viral replication following multiple low-dose challenges with the highly pathogenic SIVmac239 isolate results give hope that a vaccine designed to induce cellular immune responses might control viral replicate.
Journal ArticleDOI
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
Michael D. Miller,Romas Geleziunas,Elisabetta Bianchi,Simon N Lennard,Renee Hrin,Hangchun Zhang,Meiqing Lu,Zhiqiang An,Paolo Ingallinella,Marco Finotto,Marco Mattu,Adam C. Finnefrock,David Bramhill,Cook James C,Debra M. Eckert,Debra M. Eckert,Richard Hampton,Mayuri Patel,Stephen Jarantow,Joseph G. Joyce,Gennaro Ciliberto,Riccardo Cortese,Ping Lu,William R. Strohl,William A. Schleif,Michael McElhaugh,Steven Lane,Christopher Lloyd,David Lowe,Jane K. Osbourn,Tristan J. Vaughan,Emilio A. Emini,Emilio A. Emini,Gaetano Barbato,Peter S. Kim,Daria J. Hazuda,John W. Shiver,Antonello Pessi +37 more
TL;DR: The finding that the D5 fusion-inhibitory antibody shares the same binding site suggests that the hydrophobic pocket is a "hot spot" for fusion inhibition and an ideal target on which to focus a vaccine-elicited antibody response.
Patent
Synthetic HIV gag genes
TL;DR: Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided in this paper, which are used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through stimulation of neutralizing antibody and cell-mediated immunity.